Press release, Helsinki, 24 April 2017 at 3 pm
Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company"), a medical technology company developing and marketing pioneering navigated non-invasive brain stimulation systems for both therapeutic and diagnostic applications, announces that Aarhus University Hospital, Denmark has recently purchased a Navigated Brain Stimulation (NBS) System.
The NBS System at Aarhus University Hospital will be used for diagnostic brain mapping for the treatment of brain tumours and other neurologic related disorders.
The neurosurgeons at Aarhus University Hospital Dr. Anders Rosendal Korshoj and Dr. Gorm von Oettingen commented: "We are excited with the acquisition of Nexstim NBS and the unique diagnostic information it provides. We expect to be able to operate 25% more patients with central area tumours due to the ability of the Nexstim system to correctly plan these high-risk surgeries."
Commenting on this news, Henri Hannula, VP Sales Europe said: "We are delighted that one of the leading neurosurgical departments in Denmark has decided to acquire our unique brain mapping system. We look forward to co-operating with the team at Aarhus University Hospital and adding them to our growing international brain mapping customer group in neurosurgery."
NEXSTIM PLC
Martin Jamieson, Chairman and CEO
Further information is available on the website www.nexstim.com (http://www.nexstim.com/) or by telephone:
Nexstim +447715163942
Martin Jamieson, Chairman and CEO martin.jamieson@nexstim.com
Citigate Dewe Rogerson +44 (0)207 2821066
Katja Stout katja.stout@citigatedr.co.uk
About Nexstim Plc
Nexstim is a medical technology company a medical technology company developing and marketing pioneering navigated non-invasive brain stimulation systems for both therapeutic (NBT® system) and diagnostic (NBS system) applications. Nexstim's NBS system is the only FDA cleared and CE marked system based on navigated Transcranial Magnetic Stimulation (nTMS) for the pre-surgical mapping of the speech and motor cortices of the brain.
Based on the same technology platform, the Company has developed the Navigated Brain Therapy (NBT®) which is CE marked for the treatment of stroke, major depression and chronic neuropathic pain. The NBT® system is currently in a supplemental Phase III study, E-FIT trial, which will recruit 60 patients. The trial is expected to complete in Q1 2018 allowing Nexstim to file for FDA clearance in April 2018. FDA clearance would allow Nexstim to start marketing and selling its NBT® system for stroke rehabilitation in the USA.
Nexstim shares are listed on the Nasdaq First North Finland and Nasdaq First North Sweden. For more information please visit www.nexstim.com (http://www.nexstim.com/)
About Aarhus University Hospital
Aarhus University Hospital is a highly-specialized hospital in Central Denmark Region, one of five Danish regions.
The Department of Neurosurgery at Aarhus University Hospital is one of the leading neurosurgical departments in Denmark. The department performs general neurosurgery and highly specialized neurosurgical treatments to patients in Central Denmark Region, other Danish regions and to patients from abroad. Excellence in patient treatment is the key focus of the department and this is supported by internationally renowned research and collaborations.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Nexstim Oyj via Globenewswire
